Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$12.64

0.36 (2.93%)

04:55
07/24/18
07/24
04:55
07/24/18
04:55

Kala Pharmaceuticals management to meet with JPMorgan

Meeting to be held in New York on July 24 hosted by JPMorgan.

  • 24

    Jul

  • 24

    Aug

KALA Kala Pharmaceuticals
$12.64

0.36 (2.93%)

01/05/18
WELS
01/05/18
NO CHANGE
WELS
Outperform
Kala dry eye trial results mixed but positive, says Wells Fargo
After Kala Pharmaceuticals reported that KPI-121 demonstrated statistically significant improvements in the primary sign and symptom endpoints in one Phase 3 trial but missed for the primary symptom endpoint in another trial, Wells Fargo analyst David Maris said the mixed data "complicates things" but still show a positive drug profile for KPI-121. He would expect the shares to be down on this data, but also believes some of the risk seems to have been in expectations given the stock having been down recently. Maris keeps an Outperform rating on Kala shares, which are down 24% in morning trading.
01/25/18
WELS
01/25/18
NO CHANGE
Target $19
WELS
Outperform
Kala Pharmaceuticals price target lowered to $19 from $24 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Kala Pharmaceuticals to $19 from $24 on valuation after the shares dropped following mixed results from the two pivotal Phase III trials of its dry eye treatment, KPI-121. The analyst believes Kala's shares have the opportunity to outperform as investors shift their near-term focus to the company's post-surgical ocular steroid which has an August 2018 PDUFA. He reiterates an Outperform rating on the stock.
06/19/18
WELS
06/19/18
NO CHANGE
Target $19
WELS
Outperform
Kala Pharma's KPI-121 update suggests faster market entry, Wells Fargo says
Wells Fargo analyst David Maris kept his Outperform rating and $19 price target on Kala Pharmaceuticals, saying its announced plans to submit a new drug application for KPI-121 to the FDA in the second half of the year may expedite its market entry. The analyst adds that the most likely scenario is for the FDA to accept the company's NDA for review but ultimately consider the Stride 3 data and issue a Complete Response Letter for an additional study, which will likely lead to a class 2 resubmission and a shortened 6-month review period. Maris contends that it is also possible that the FDA "accepts Kala's NDA, finds the existing data to be sufficient, and approves KPI-121 0.25% in its first review cycle, leading to a late-2019 or early 2020 commercialization.
07/23/18
HCWC
07/23/18
INITIATION
Target $35
HCWC
Buy
Kala Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Kala Pharmaceuticals with a Buy rating and $35 price target. The current valuation provides an "intriguing entry point" for investors ahead of the "risk-mitigated catalyst," the potential approval of Inveltys, Selvaraju tells investors in a research note. The analyst has "high confidence" that the drug should be approved in a "timely manner."

TODAY'S FREE FLY STORIES

09:45
05/22/19
05/22
09:45
05/22/19
09:45
Hot Stocks
Breaking Hot Stocks news story  »

Liberty Global Plc…

09:45
05/22/19
05/22
09:45
05/22/19
09:45
General news
Breaking General news story  »

New York Federal Reserve…

HELE

Helen of Troy

$136.94

(0.00%)

09:43
05/22/19
05/22
09:43
05/22/19
09:43
Recommendations
Helen of Troy analyst commentary  »

Helen of Troy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITB

iShares U.S. Home Construction ETF

$38.26

(0.00%)

, LOW

Lowe's

$111.10

(0.00%)

09:40
05/22/19
05/22
09:40
05/22/19
09:40
Options
Unusually active option classes on open May 22nd »

Unusual total active…

ITB

iShares U.S. Home Construction ETF

$38.26

(0.00%)

LOW

Lowe's

$111.10

(0.00%)

TGT

Target

$72.05

(0.00%)

MYL

Mylan

$19.67

(0.00%)

SLB

Schlumberger

$39.50

(0.00%)

CRON

Cronos Group

$15.60

(0.00%)

NFLX

Netflix

$354.33

(0.00%)

SBUX

Starbucks

$77.56

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 06

    Jun

  • 12

    Jun

  • 18

    Jun

  • 24

    Jun

  • 25

    Jun

  • 09

    Jul

  • 13

    Nov

BRID

Bridgford Foods

$29.00

(0.00%)

09:40
05/22/19
05/22
09:40
05/22/19
09:40
Hot Stocks
Breaking Hot Stocks news story on Bridgford Foods »

Bridgford Foods trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$77.16

-1.16 (-1.48%)

, S

Sprint

$7.21

-0.13 (-1.77%)

09:39
05/22/19
05/22
09:39
05/22/19
09:39
Periodicals
DOJ staff favor blocking T-Mobile/Sprint deal, top brass to decide, Reuters says »

The Justice…

TMUS

T-Mobile

$77.16

-1.16 (-1.48%)

S

Sprint

$7.21

-0.13 (-1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BRID

Bridgford Foods

$29.00

-0.12 (-0.41%)

09:35
05/22/19
05/22
09:35
05/22/19
09:35
Hot Stocks
Breaking Hot Stocks news story on Bridgford Foods »

Bridgford Foods trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$36.89

1.21 (3.39%)

09:34
05/22/19
05/22
09:34
05/22/19
09:34
Upgrade
Legg Mason rating change  »

Legg Mason upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSX

Diana Shipping

$3.30

0.01 (0.30%)

09:32
05/22/19
05/22
09:32
05/22/19
09:32
Hot Stocks
Diana Shipping announces time charter contract for m/v Baltimore with Koch »

Diana Shipping announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEL

Xcel Energy

09:30
05/22/19
05/22
09:30
05/22/19
09:30
Recommendations
Xcel Energy analyst commentary  »

Xcel Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

PPC

Pilgrim's Pride

09:30
05/22/19
05/22
09:30
05/22/19
09:30
Upgrade
Pilgrim's Pride rating change  »

Pilgrim's Pride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

SAFM

Sanderson Farms

$146.80

-2.17 (-1.46%)

09:30
05/22/19
05/22
09:30
05/22/19
09:30
Upgrade
Sanderson Farms rating change at Cleveland Research »

Sanderson Farms upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 13

    Nov

09:30
05/22/19
05/22
09:30
05/22/19
09:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

CAH

Cardinal Health

$46.90

0.91 (1.98%)

09:25
05/22/19
05/22
09:25
05/22/19
09:25
Conference/Events
Morgan Stanley healthcare tech analyst to hold analyst/industry conference call »

Healthcare Technology and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

  • 23

    Jun

HMN

Horace Mann

$39.76

0.095 (0.24%)

09:22
05/22/19
05/22
09:22
05/22/19
09:22
Initiation
Horace Mann initiated  »

Sandler O'Neill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

OSTK

Overstock.com

$11.19

1.305 (13.21%)

09:21
05/22/19
05/22
09:21
05/22/19
09:21
Hot Stocks
Overstock.com subsidiary MLG signs MOU with Lusaka City Council »

Overstock.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:20
05/22/19
05/22
09:20
05/22/19
09:20
General news
Treasury Action: Treasury Secretary Mnuchin said there are no plans yet to go to Beijing »

Treasury Action: Treasury…

AMBA

Ambarella

, ON

ON Semiconductor

$18.74

0.41 (2.24%)

09:18
05/22/19
05/22
09:18
05/22/19
09:18
Recommendations
Ambarella, ON Semiconductor analyst commentary  »

Ambarella revenue could…

AMBA

Ambarella

ON

ON Semiconductor

$18.74

0.41 (2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 04

    Jun

  • 06

    Jun

TOCA

Tocagen

$8.81

-0.18 (-2.00%)

09:18
05/22/19
05/22
09:18
05/22/19
09:18
Recommendations
Tocagen analyst commentary  »

SVB Leerink says Tocagen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

EKSO

Ekso Bionics

$1.84

-0.06 (-3.16%)

09:18
05/22/19
05/22
09:18
05/22/19
09:18
Syndicate
Ekso Bionics 6.667M share Spot Secondary priced at $1.50 »

Cantor Fitzgerald and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 22

    May

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
05/22/19
05/22
09:18
05/22/19
09:18
Options
Overnight activity included 567 trades in SPX and 6 trades in VIX »

567 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNJN

Finjan Holdings

$2.58

-0.07 (-2.64%)

09:17
05/22/19
05/22
09:17
05/22/19
09:17
Hot Stocks
Finjan Holdings CFO Michael Noonan to depart company, Jevan Anderson to succeed »

Finjan Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 19

    Jun

EXPE

Expedia

$117.13

1.02 (0.88%)

09:16
05/22/19
05/22
09:16
05/22/19
09:16
Downgrade
Expedia rating change  »

Expedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

WLTW

Willis Towers Watson

$178.33

1.87 (1.06%)

, MSFT

Microsoft

$126.90

0.71 (0.56%)

09:14
05/22/19
05/22
09:14
05/22/19
09:14
Hot Stocks
Willis Towers Watson announces quantum computing collaboration with Microsoft »

Willis Towers Watson…

WLTW

Willis Towers Watson

$178.33

1.87 (1.06%)

MSFT

Microsoft

$126.90

0.71 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 19

    Jun

  • 23

    Jun

  • 06

    Aug

TOCA

Tocagen

$8.81

-0.18 (-2.00%)

09:13
05/22/19
05/22
09:13
05/22/19
09:13
Recommendations
Tocagen analyst commentary  »

Tocagen dismissive views…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.